benzbromarone uricosuric agent noncompetitive inhibitor xanthine used treatment gout especially allopurinol firstline treatment fails produces intolerable adverse effects structurally related antiarrhythmic benzbromarone highly effective well clinical trials early recently april suggested superior allopurinol nonuricosuric xanthine oxidase inhibitor probenecid another uricosuric benzbromarone potent inhibitor several analogues drug developed inhibitors use benzbromarone introduced viewed associated serious adverse reactions registered countries throughout europe asia south america drug withdrawn sanofisynth√©labo reports serious hepatotoxicity although still marketed several countries drug httpsenwikipediaorgwikibenzbromarone